FDA
-
-
-
-
-
-
-
Monopar Announces Completion of Phase 2b Enrollment and Commencement of Phase 3 Enrollment in its VOICE Trial for Severe Oral Mucositis
-
-
-
-
-
-
-
Monopar Therapeutics Reports Third Quarter 2021 Financial Results and Recent Clinical Developments
-
-
-
-
-
-
-
Monopar Therapeutics (MNPR) Announces FDA Clearance to Proceed with Camsirubicin Clinical Trial Targeting Advanced Soft Tissue Sarcoma
-
-
-
-
-
-
-
Monopar and NorthStar Announce Patent Filing on Promising Radiopharmaceutical Discovery
-
-
-
-
-
-
-
Monopar Announces First Patient Dosed in its Phase 2b/3 VOICE Trial Evaluating Validive® for the Prevention of Chemoradiotherapy-Induced Severe Oral Mucositis (SOM) in Oropharyngeal Cancer (OPC)
-
-
-
-
-
-
-
Monopar Announces Initiation of its Phase 2b/3 (VOICE) Trial to Evaluate Validive® for the Prevention of Chemoradiotherapy-Induced Severe Oral Mucositis (SOM) in Oropharyngeal Cancer (OPC)
-
-
-
-
-
-
-
Monopar and NorthStar Collaborating with Texas Lung Injury Institute for Testing of Novel Potential Therapeutic for Severe COVID-19
-
251,413 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All